antiarrhythmic therapy

antiarrhythmic therapy

Cardiology The use of therapeutic agents to counteract potentially life-threatening and refractory ventricular arrhythmias, and ↓ mortality; the Vaughn Williams/Harrison classification divides antiarrhythmic agents into 5 groups. Cf Proarrhythmic effect.
References in periodicals archive ?
In collaboration with members of the UCLA Cardiovascular Research Laboratory (CVRL), Numerate will use the funds to support the discovery of novel, small molecule drug candidates that address the need for a well-tolerated antiarrhythmic therapy for the treatment and prevention of ventricular tachycardias and fibrillation (VT/VF).
For most patients with primary tachyarrhythmias, they can be successfully managed with appropriate antiarrhythmic therapy, overdrive pacing, direct current cardioversion, and, if necessary, timely ablation.[4] However, these therapies are not always effective.
Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter.
The lack of a 24-hour Holter ECG and a second electrocardiogram to evaluate the effectiveness of digoxin antiarrhythmic therapy for supraventricular trigeminy are limitations of the present report.
Patients with ongoing antiarrhythmic therapy were also excluded.
At this point, we decided the discontinuation of flecainide therapy while continuing the antiarrhythmic therapy with lidocaine and adding a beta blocker.
Patients were divided into three groups: group A included patients with no POAF prophylaxis; group B included patients with diltiazem prophylaxis; and group C included patients with preoperative antiarrhythmic therapy (mostly beta-blockers, a few propafenone or amiodarone) that was continued postoperatively.
Despite antiarrhythmic therapy, the patient continued to have symptomatic atrial fibrillation with palpitations but no shortness of breath.
Depending on underlying diseases, antiarrhythmic therapy is recommended [19].
Oral antiarrhythmic therapy may be required, because attempts to wean patients from isoproterenol can result in recurrent VF.
Findings could lead to new efforts to better man-age AF by gender, including antiarrhythmic therapy and radiofrequency ablation, researchers write.
Indeed, the future of antiarrhythmic therapy lies in neuromodulation of the autonomic nervous system, and it's a lot closer than most cardiologists realize, according to the electrophysiologist.